The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)

Authors

• Robert Chen
• Baevin Carbery
• Lisa Mac
• Kenneth Berns
• Louisa Chapman
• Richard Condit
• Jean-Louis Excler
• Marc Gurwith
• Michael Hendry
• Arifa Khan
• Najwa Khuri-Bulos
• Bettina Klug
• James Robertson
• Stephen J. Seligman, New York Medical CollegeFollow
• Rebecca Sheets
• Anna-Lise Williamson

Author Type(s)

Faculty

DOI

10.1016/j.vaccine.2014.09.035

Journal Title

Vaccine

First Page

73

Last Page

75

Document Type

Article

Publication Date

1-1-2015

Department

Medicine

Keywords

Clinical Trials as Topic, Drug Carriers, Drug-Related Side Effects and Adverse Reactions, Genetic Vectors, Humans, International Cooperation, Vaccines, Synthetic, Viral Vaccines

Disciplines

Medicine and Health Sciences

Abstract

Recombinant viral vectors provide an effective means for heterologous antigen expression in vivo and thus represent promising platforms for developing novel vaccines against human pathogens from Ebola to tuberculosis. An increasing number of candidate viral vector vaccines are entering human clinical trials. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to improve our ability to anticipate potential safety issues and meaningfully assess or interpret safety data, thereby facilitating greater public acceptance when licensed.

Recommended Citation

Chen, R., Carbery, B., Mac, L., Berns, K., Chapman, L., Condit, R., Excler, J., Gurwith, M., Hendry, M., Khan, A., Khuri-Bulos, N., Klug, B., Robertson, J., Seligman, S. J., Sheets, R., & Williamson, A. (2015). The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Vaccine, 33 (1), 73-75. https://doi.org/10.1016/j.vaccine.2014.09.035